Terms: = Kidney tumors AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
19 results:
1. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
[TBL] [Abstract] [Full Text] [Related]
2. Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells.
Allen A; Gau D; Francoeur P; Sturm J; Wang Y; Martin R; Maranchie J; Duensing A; Kaczorowski A; Duensing S; Wu L; Lotze MT; Koes D; Storkus WJ; Roy P
J Biol Chem; 2020 Nov; 295(46):15636-15649. PubMed ID: 32883810
[TBL] [Abstract] [Full Text] [Related]
3. Decreased Preoperative Estimated Glomerular Filtration Rate Was Related With Poor Prognosis of NSCLC Patients.
Jia W; Wang C; Cheng Y
Technol Cancer Res Treat; 2020; 19():1533033820952355. PubMed ID: 32815459
[TBL] [Abstract] [Full Text] [Related]
4. Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.
Fahy AS; Roberts A; Nasr A; Irwin MS; Gerstle JT
J Pediatr Surg; 2019 Aug; 54(8):1632-1637. PubMed ID: 30029845
[TBL] [Abstract] [Full Text] [Related]
5. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R; Miyazaki J; Ichioka D; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Kawai K; Nishiyama H
Clin Exp Nephrol; 2017 Aug; 21(4):732-740. PubMed ID: 27565169
[TBL] [Abstract] [Full Text] [Related]
6. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract] [Full Text] [Related]
7. [clinical outcome of Laparoscopic Partial Nephrectomy].
Okamoto M; Taguchi I; Okuno M; Ishida T; Okamura Y; Kawabata G
Hinyokika Kiyo; 2015 Aug; 61(8):317-20. PubMed ID: 26411653
[TBL] [Abstract] [Full Text] [Related]
8. Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.
Lin CL; Chien RN; Yeh C; Hsu CW; Chang ML; Chen YC; Yeh CT
Scand J Gastroenterol; 2014 Dec; 49(12):1456-64. PubMed ID: 25283499
[TBL] [Abstract] [Full Text] [Related]
9. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
[TBL] [Abstract] [Full Text] [Related]
10. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice.
Kleber M; Cybulla M; Bauchmüller K; Ihorst G; Koch B; Engelhardt M
Ann Oncol; 2007 May; 18(5):950-8. PubMed ID: 17351260
[TBL] [Abstract] [Full Text] [Related]
11. Frequency and clinicopathologic correlates of erbb1, erbb2, and erbb3 immunoreactivity in urothelial tumors of upper urinary tract.
Tsai YS; Tzai TS; Chow NH; Wu CL
Urology; 2005 Dec; 66(6):1197-202. PubMed ID: 16360440
[TBL] [Abstract] [Full Text] [Related]
12. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Jermann M; Stahel RA; Salzberg M; Cerny T; Joerger M; Gillessen S; Morant R; Egli F; Rhyner K; Bauer JA; Pless M
Cancer Chemother Pharmacol; 2006 Apr; 57(4):533-9. PubMed ID: 16052341
[TBL] [Abstract] [Full Text] [Related]
13. The pT1a and pT1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology?
Langner C; Ratschek M; Rehak P; Tsybrovskyy O; Zigeuner R
BJU Int; 2005 Feb; 95(3):310-4. PubMed ID: 15679784
[TBL] [Abstract] [Full Text] [Related]
14. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
Kim ES
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
[TBL] [Abstract] [Full Text] [Related]
15. [EGF receptors in urological cancer. Molecular basis and therapeutic involvements].
Paule B; Brion N
Ann Med Interne (Paris); 2003 Nov; 154(7):448-56. PubMed ID: 14732836
[TBL] [Abstract] [Full Text] [Related]
16. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract] [Full Text] [Related]
17. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor content in human renal cell carcinomas.
Yoshida K; Tosaka A; Takeuchi S; Kobayashi N
Cancer; 1994 Apr; 73(7):1913-8. PubMed ID: 8137218
[TBL] [Abstract] [Full Text] [Related]
19. Transitional cell carcinoma of the renal pelvis and its expression of p53 protein, c-erbb-2 protein, neuron-specific enolase, Phe 5, chromogranin, laminin and collagen type IV.
Bjerkehagen B; Fosså SD; Raabe N; Holm R; Nesland JM
Eur Urol; 1994; 26(4):334-9. PubMed ID: 7713133
[TBL] [Abstract] [Full Text] [Related]
